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Commission on Economic Aspects of Epilepsy 
THE IMPORTANCE OF ECONOMIC ASPECTS 
Epilepsy is an economic burden for people with 
epilepsy and for the community. Patients with 
epilepsy have to cope with the economic conse- 
quences, for example unemployment or underemploy- 
ment. Epilepsy also has a major economic impact on 
society as a whole. As recent studies in various coun- 
tries show, a considerable amount of health-care ex- 
penditure is spent on people with epilepsy. 
Economic factors are playing an increasing role 
in decision-making processes today and determine 
the standard of epilepsy care. It has come to be 
recognized that the costs have a significant impact 
on the distribution of epilepsy services. The Inter- 
national League against Epilepsy (ILAE) has seen 
the importance of economic aspects for the devel- 
opment of epilepsy care. Therefore, two years ago, 
Ted Reynolds, President of the ILAE established a 
new body, the Commission on Economic Aspects of 
Epilepsy. 
First, we have to realize that financial resources 
for the health care sector are limited This was a 
fact before politicians and economic experts began 
to talk about curbing the cost of health care; limited 
resources are not a historic exception but the nor- 
mal situation. From a historic viewpoint periods of 
rapid growth are usually quite short. The idea that 
our health-care system is able to offer the maximum 
of health care to all its members might be a tempting 
illusion but it simply is not true. Even today, in a 
small and rich country like Switzerland, health-care 
services are unevenly spread through the country. 
Secondly, political decisions about a budget or a 
project are often based on economic arguments. Cost- 
benefit considerations guide decisions on the alloca- 
tion of health-care services, Major‘investments have 
to be based on cost-benefit studies. For example, in 
the case of major investment in epilepsy surgery, 
cost-benefit studies are particularly needed. Further 
to this, the introduction of new antiepileptic drugs 
(AED), prior to registration and recovery of costs 
from health budgets, have to show that their cost ef- 
fectiveness is reasonable in comparison with those 
drugs, already available. 
Measured against the massive influence of finance 
on the availability of epilepsy services, we have to re- 
alize that little is known about the real cost of epilepsy 
and the economic benefit of a particular type of treat- 
ment. 
THE COST OF EPILEPSY 
In discussing the cost of epilepsy today, a distinction 
must be drawn between the cost to the individual pa- 
tient and the cost of epilepsy care to society at large. 
It is important to see that epilepsy is an economic 
burden for the individual patient. Many patients with 
epilepsy have to cope with unemployment or under- 
employment. This is generally felt to be more serious 
than the additional cost occasioned by epilepsy. 
Epilepsy also has a major economic impact on the 
community as a whole. In the health economy, the 
issue of ‘cost of illness’ has been discussed for some 
time. The term ‘cost of illness’ means the total cost 
that arises for the community of a particular illness, 
such as the cost of diabetes, rheumatism or AIDS. 
Only recently has this kind of calculation been ap- 
plied to the illness of epilepsy. Such studies about 
the‘cost of epilepsy in the UK, USA, Australia, Swe- 
den, Switzerland, and other countries were presented 
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to the International Epilepsy Congress in Oslo about 
2; years ago’. A comparison of different studies on 
the cost of epilepsy shows that there are various mod- 
els for the calculation of that cost. However, as yet, 
no standard model is available for the assessment of 
the costs of epilepsy. Agreement simply exists on the 
need to make a distinction between different types of 
costs. 
1. Direct cost: medical costs (institutional inpa- 
tient care, outpatient services, drug costs, etc.) 
and non-medical costs (care provided by the 
family, social services, etc.). 
2. Indirect cost: loss of earnings due to unemploy- 
ment, underemployment, excess mortality, etc. 
3. Intangible cost: impairment of the quality of 
life, social isolation, pain, stigma, etc. 
The studies carried out up to now do not show a 
uniform picture. Also they make use of different mod- 
els for calculating costs. Some studies leave out the 
non-medical costs, whilst others take into account dis- 
ability pensions. However, we recommend that nei- 
ther disability pensions nor unemployment benefit be 
included, as these are considered to be transfer pay- 
ments. 
When discussing these different models, we came 
to the basic conclusion that only those costs that 
should be taken into account are, those incurred di- 
rectly by epilepsy. The results would be unrepresenta- 
tive if all costs for all people suffering from epilepsy 
were calculated. For many handicapped patients hav- 
ing seizures, the high cost of nursing is not only 
caused by epilepsy. In other words curing epilepsy 
would not mean that costs of caring for these handi- 
capped patients would be removed. 
Furthermore, the calculation of the cost is just one 
side of the cost-benefit equation. The cost of epilepsy 
care does not tell us much about its effectiveness. 
Therefore, economic arguments always have to be 
based on both cost and benefit. 
THE COST-BENEFIT EVALUATIONS 
A precondition of cost-benefit evaluations is that one 
must be able to quantify the benefit side in some way. 
A widely used standard is, for example, the reduction 
of the seizure frequency. For people suffering from 
epilepsy, this is generally an important factor in their 
quality of life. However, there can be no doubt that 
this is not the only criteria for the benefits. There 
are other indicators for measuring the benefit of a 
particular treatment. For this reason, the ILAE has 
established a special commission for the subject of 
‘Outcome Measurement’. 
C. Pachlatko 
From the economical viewpoint, the costs of new 
AED are a current theme. Charles Begley ef al ’ 
(1994) in their study ‘Cost of epilepsy in the USA’, 
found that AED take up 38% of the total medical 
costs of epilepsy. Even if the proportion of drug costs 
in this study appears relatively high, it can be seen 
that the AED costs are significant. 
The costs of AED have, therefore, been brought 
into the spotlight, because new drugs are several 
times more expensive than older, more familiar drugs. 
David Chadwick, chairman of the ILAE Commission 
on Anti-epileptic Drugs, stated that treatment with the 
new medicines can be more than 100 times more ex- 
pensive than treatment with phenobarbital. This is, of 
course, due to the extraordinary low price of pheno- 
barbital, which has been used as a basis for compar- 
ison. The higher costs, however, are impressive and 
enhance the need for economic evaluation. 
Comparison between old and new drugs raises the 
question of additional costs and additional benefits. 
The comparison of cost with benefit has a major polit- 
ical impact on the reimbursement and distribution of 
new AED. The authorities who finance the medicines 
have an interest in testing the economical effective- 
ness of a new drug. This means that, alongside the 
medical effect, the economic efSectiveness of the new 
dmg must also be proved. 
For providers of epilepsy services, economics must 
not be allowed to result in a situation in which eco- 
nomic goals become an end in themselves. On the 
contrary, economics must help to ensure the better 
attainment of the goals of epilepsy care. A better 
knowledge of the economic factors will improve the 
further development of epilepsy services, particularly 
the development and registration of new AED. 
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